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Abstract
BACKGROUND—Children with febrile urinary tract infection commonly have vesicoureteral
reflux. Because trial results have been limited and inconsistent, the use of antimicrobial
prophylaxis to prevent recurrences in children with reflux remains controversial.
METHODS—In this 2-year, multisite, randomized, placebo-controlled trial involving 607
children with vesicoureteral reflux that was diagnosed after a first or second febrile or
symptomatic urinary tract infection, we evaluated the efficacy of trimethoprim–sulfamethoxazole
prophylaxis in preventing recurrences (primary outcome). Secondary outcomes were renal
scarring, treatment failure (a composite of recurrences and scarring), and antimicrobial resistance.
RESULTS—Recurrent urinary tract infection developed in 39 of 302 children who received
prophylaxis as compared with 72 of 305 children who received placebo (relative risk, 0.55; 95%
confidence interval [CI], 0.38 to 0.78). Prophylaxis reduced the risk of recurrences by 50%
(hazard ratio, 0.50; 95% CI, 0.34 to 0.74) and was particularly effective in children whose index
infection was febrile (hazard ratio, 0.41; 95% CI, 0.26 to 0.64) and in those with baseline bladder
and bowel dysfunction (hazard ratio, 0.21; 95% CI, 0.08 to 0.58). The occurrence of renal scarring
did not differ significantly between the prophylaxis and placebo groups (11.9% and 10.2%,
respectively). Among 87 children with a first recurrence caused by Escherichia coli, the
proportion of isolates that were resistant to trimethoprim–sulfamethoxazole was 63% in the
prophylaxis group and 19% in the placebo group.
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CONCLUSIONS—Among children with vesicoureteral reflux after urinary tract infection,
antimicrobial prophylaxis was associated with a substantially reduced risk of recurrence but not of
renal scarring. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases
and others; RIVUR ClinicalTrials.gov number, NCT00405704.)
Vesicoureteral reflux is present in one third of children presenting with febrile urinary tract
infection and has been associated with a heightened risk of renal scarring. 1 Early
randomized, controlled trials that compared antireflux surgery with antimicrobial
prophylaxis showed no significant differences in the rates of recurrent urinary tract infection
(recurrences) and renal scarring2–5; however, the lack of a placebo or observation group
precluded a determination that either surgery or prophylaxis was effective. More recent
randomized trials, most of which were unblinded, have had conflicting results regarding the
effectiveness of anti-microbial prophylaxis in reducing recurrences.6–11 We designed the
Randomized Intervention for Children with Vesicoureteral Reflux (RIVUR) trial to
determine whether long-term antimicrobial prophylaxis is effective in preventing febrile or
symptomatic recurrences and reducing the likelihood of renal scarring, and the extent to
which it contributes to bacterial resistance.
METHODS
STUDY DESIGN AND OVERSIGHT
The study was a randomized, double-blind, placebo-controlled trial of prophylaxis with
trimethoprim–sulfamethoxazole (Sulfatrim Pediatric suspension from Actavis and
Sulfamethoxazole and Trimethoprim Oral Suspension from Hi-Tech Pharmacal) in children
with vesicoureteral reflux that was diagnosed after a first or second febrile or symptomatic
urinary tract infection (index infection). The project steering committee designed the trial,
which was sponsored by the National Institute of Diabetes and Digestive and Kidney
Diseases (NIDDK) and was conducted under an Investigational New Drug application
(number 75,739) to the Food and Drug Administration. The study rationale and design have
been published previously,12–16 and the protocol is available with the full text of this article
at NEJM.org. The writing group wrote the manuscript and vouches for the completeness and
accuracy of the data and analyses and the fidelity of the study to the protocol.
We enrolled children at 19 clinical sites across the United States who were 2 to 71 months of
age and had grade I to IV vesicoureteral reflux. We excluded children whose index infection
occurred more than 112 days before randomization and children with coexisting urologic
anomalies, contraindications for the use of trimethoprim–sulfamethoxazole, or certain
medical conditions (see the Supplementary Appendix, available at NEJM.org). We followed
the children for 2 years to ascertain the primary outcome of febrile or symptomatic
recurrence and secondary outcomes of renal scarring, failure of prophylaxis, and
antimicrobial resistance. We also assessed bladder and bowel dysfunction according to a
standardized measure (see the Supplementary Appendix).12,17,18 An NIDDK data and safety
monitoring board and an institutional review board at each site approved the protocol.
Parents or legal guardians of the children provided written informed consent before
enrollment.
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Randomization was performed in permuted blocks, stratified according to site. Data
management and statistical analyses were performed by a data-coordinating center at the
University of North Carolina at Chapel Hill. We randomly assigned children to receive daily
trimethoprim–sulfamethoxazole suspension (3 mg of trimethoprim plus 15 mg of
sulfamethoxazole per kilogram of body weight) or placebo (prepared by UPM
Pharmaceuticals) that was nearly identical in color, smell, taste, and consistency. Four
persons at the data-coordinating center managed the linkage of study-group assignments
with study medications; the data-management software confirmed the eligibility of each
child and generated assignments to coded bottles of study medication.
STUDY PROCEDURES
Urine specimens from children who were not toilet trained were obtained by means of
catheterization or suprapubic aspiration; bag-collected specimens were not permitted. Clean,
voided specimens were collected from toilet-trained children. Index and outcome infections
met stringent diagnostic criteria that included evidence of pyuria on urinalysis, culture-
proven infection, and fever (≥38°C) or urinary tract symptoms within 24 hours before or
after urine collection.12,14 Renal scanning with technetium-99m–labeled dimercaptosuccinic
acid was performed at baseline and after 1 and 2 years. Two pediatric nuclear-medicine
physicians assessed the extent of renal cortical defects semiquantitatively by dividing the
cortex into 12 segments and determined severity on the basis of the number of segments
affected. Treatment failure was defined as two febrile recurrences, one febrile and three
symptomatic recurrences, or four symptomatic recurrences over the course of the study or as
new or worsening scarring at 1 year.14
At baseline, after the occurrence of treatment failure, and at 24 months, we obtained rectal
swabs, which were tested in a central laboratory for resistance of Escherichia coli isolates to
trimethoprim–sulfamethoxazole.19 We also assessed, at local laboratories, resistance among
pathogens identified in children with recurrences.
STATISTICAL ANALYSIS
We estimated that a sample of 300 children in each study group would provide at least 80%
power to detect a reduction in the proportion of children with febrile or symptomatic
recurrences during a 2-year follow-up period from 20% in the placebo group to 10% in the
trimethoprim–sulfamethoxazole group, at a two-sided alpha level of 0.05. Our a priori plan
called for an intention-to-treat analysis of recurrences, stratified according to site, with the
use of a Cochran–Mantel–Haenszel test with missing outcomes imputed as events, as well as
time-to-event analyses with the use of a stratified log-rank test. We used Kaplan–Meier
estimates to describe the proportions of children who had febrile or symptomatic recurrences
or who met the criteria for treatment failure. We used Cox models both in analyses of
treatment effects according to age, sex, severity of reflux, and other factors and in analyses
that were controlled for multiple factors. We used Fisher’s exact test to compare adverse
events in the two study groups. Reported P values have not been adjusted for multiple
comparisons; a P value of less than 0.046 was considered to indicate statistical significance
for the primary outcome. Sensitivity analyses of febrile or symptomatic recurrences were
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performed, first, by including children for whom outcome data were missing and classifying
them as not having had an event and, second, by omitting such children from the analyses.
RESULTS
STUDY PARTICIPANTS
We screened and enrolled children between June 2007 and May 2011; however, capture of
screening data began in November 2007. Of 10,871 children with screening data available,
1426 (13.1%) met the eligibility criteria, of whom 607 (42.6%) were enrolled. For 115 of the
607 children enrolled who met all the eligibility criteria in the course of the study,
corresponding screening data for those not enrolled were not available (Fig. 1). Follow-up
was completed in June 2013. Baseline demographic and clinical characteristics of the trial
participants have been reported previously.12 Briefly, 554 children (91.3%) were enrolled
after their first urinary tract infection; the index infection was febrile in 521 children
(85.8%). The median age was 12 months, and 558 (91.9%) of the children were girls. A total
of 484 of 602 children (80.4%) had grade II or III vesicoureteral reflux; 287 of 600 children
(47.8%) had bilateral reflux. Of 126 toilet-trained children, 71 (56.3%) had symptoms of
bladder and bowel dysfunction. No significant differences in sex, race, or ethnic group were
apparent between enrolled children and those who were screened but not enrolled. The study
groups did not differ significantly with respect to any baseline characteristic (Table 1).
ADHERENCE
Parents of 467 of the children (76.9%) reported having administered the study medication at
least 75% of the time, and parents of 517 children (85.2%) reported having administered it at
least 50% of the time. Parents of 91 children in the prophylaxis group and of 76 children in
the placebo group discontinued the study medication. No significant difference in reported
adherence to the study-medication regimen was noted between the study groups.
RECURRENCES OF FEBRILE OR SYMPTOMATIC URINARY TRACT INFECTION
During the trial, 111 children had 171 recurrences of urinary tract infection (Table 2, and
Table S1 in the Supplementary Appendix). Of 111 first recurrences, 80 (72.1%) were
febrile; 2 first recurrences took place after 24 months but before the study exit visit. The risk
of febrile or symptomatic recurrences was reduced by half among children who received
prophylaxis as compared with those who received placebo, and the difference between the
two groups widened progressively over time (hazard ratio, 0.50; 95% confidence interval
[CI], 0.34 to 0.74) (Fig. 2 and 3). The interval between enrollment and a 10% incidence of
recurrence was 336 days in the prophylaxis group and 106 days in the placebo group. Eight
children (95% CI, 5 to 16) would have had to be treated for 2 years to prevent one case of
febrile or symptomatic urinary tract infection.
In our primary intention-to-treat analysis with the assumption that children with missing
primary-outcome data had had an event, a significantly smaller proportion of children who
received prophylaxis, as compared with those who received placebo, had a febrile or
symptomatic recurrence (25.5% vs. 37.4%; relative risk, 0.68; 95% CI, 0.53 to 0.87) (Table
2). Similar results were obtained from sensitivity analyses that included children with
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missing outcome data but assumed they had not had an event (12.8% vs. 25.4%; relative
risk, 0.55; 95% CI, 0.38 to 0.78) and that omitted children for whom primary-outcome data
were missing (14.8% vs. 27.4%; relative risk, 0.54; 95% CI, 0.38 to 0.77). The proportion of
children meeting the criteria for treatment failure in the placebo group was nearly twice the
proportion in the prophylaxis group (9.6% vs. 5.0%, P = 0.035). In separate Cox models, the
study-group effect remained unchanged after we controlled for age, whether the index
urinary tract infection was the child’s first or second episode, the degree of baseline reflux,
and the presence or absence of baseline renal scarring (Table S2 in the Supplementary
Appendix).
RENAL SCARRING
As reported previously,12 a total of 98 of 582 baseline scans were obtained less than 31 days
after the index infection (16.8%), and 484 were obtained between 31 and 112 days after the
index infection (83.2%). A total of 21 scans (3.6%) were interpreted as indicating renal
scarring, and 71 (12.2%) were interpreted as indicating acute pyelonephritis. Outcome scans
(at the 2-year visit or 3 to 4 months after the child had met treatment-failure criteria) showed
no significant between-group differences in the incidence of renal scarring (11.9% in the
prophylaxis group and 10.2% in the placebo group, P = 0.55), severe renal scars (4.0% and
2.6%, respectively; P = 0.37), or new renal scars since baseline (8.2% and 8.4%,
respectively; P = 0.94) (Table 2).
ANTIMICROBIAL RESISTANCE
Stool colonization with resistant E. coli was more common in the prophylaxis group than in
the placebo group, but the difference was not significant (Table 2). Among 87 children with
a first febrile or symptomatic recurrence with E. coli, the proportion of isolates that were
resistant to trimethoprim–sulfamethoxazole was 63% with prophylaxis and 19% with
placebo (P<0.001).
EFFECT MODIFIERS
Children with grade III or IV reflux at baseline were more likely to have febrile or
symptomatic recurrences than were children with grade I or II reflux (64 of 280 children
[22.9%] vs. 46 of 322 [14.3%], P = 0.003). Hazard ratios for recurrences consistently
favored the prophylaxis group, irrespective of sex, age at study entry, degree of reflux,
whether children had one or two urinary tract infections before enrollment, whether the
index infection was caused by a resistant pathogen, and whether reflux present at baseline
had resolved, improved, not changed, or worsened at 2 years (Fig. 3). There were significant
interactions between study group and the type of index infection (P = 0.04) and between
study group and the presence or absence of bladder and bowel dysfunction at baseline (P =
0.02). The estimated hazard ratio for a febrile or symptomatic recurrence in the prophylaxis
group relative to the placebo group was 0.41 (95% CI, 0.26 to 0.64) among children with a
febrile index infection and 1.28 (95% CI, 0.47 to 3.46) among children with a nonfebrile
index infection. Corresponding hazard ratios for children with and those without bladder and
bowel dysfunction at baseline were 0.21 (95% CI, 0.08 to 0.58) and 1.40 (95% CI, 0.43 to
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4.58). The study population included too few boys to evaluate the effect of circumcision, but
all four boys with a first recurrence were uncircumcised at baseline.
REFLUX STATUS AT 2 YEARS
Voiding cystourethrography was performed at 2 years in 428 children. Reflux was
considered to be resolved in 218 children (50.9%), improved in 100 (23.4%), unchanged in
79 (18.5%), and worse in 31 (7.2%).
ADVERSE EVENTS
We found no significant between-group differences in the proportions of children with fever
(14.2% in the prophylaxis group and 18.0% in the placebo group, P = 0.23), otitis media
(4.3% and 7.9%, respectively; P = 0.09), diarrhea (3.6% and 6.2%, P = 0.19), pharyngitis
(6.3% and 4.6%, P = 0.38), rash (7.6% and 7.5%, P = 1.0), or viral infection (4.6% and
5.2%, P = 0.85) (Table S3 in the Supplementary Appendix). Hospitalizations or emergency
room visits also did not differ significantly between the prophylaxis and placebo groups
(41.1% and 48.5%, respectively; P = 0.06) (Table S4 in the Supplementary Appendix).
DISCUSSION
Antimicrobial prophylaxis in children with vesicoureteral reflux diagnosed after a first or
second urinary tract infection was associated with a halving of the risk of febrile or
symptomatic recurrences. Differences between the prophylaxis and placebo groups were
apparent early on and increased over a 2-year period. Children with bladder and bowel
dysfunction at baseline and children whose index infection was febrile derived particular
benefit from prophylaxis, with reductions in recurrences of approximately 80% and 60%,
respectively. Rates of renal scarring at the outcome visit were low and were not reduced by
prophylaxis, perhaps because most children were enrolled after their first infection and
because parents, who were instructed to be vigilant, sought early medical attention. Not
unexpectedly, recurrences that did occur in children who received prophylaxis were more
likely to have been caused by a resistant pathogen.
We designed our trial to avoid certain limitations of previous studies.2–11,20 We enrolled,
from a variety of clinical settings, a large, representative sample of children with
vesicoureteral reflux (grade I to IV) that was diagnosed after a urinary tract infection. We
applied stringent diagnostic criteria and used standardized scales to identify predisposing
factors.12 Our radiologists applied standardized criteria to enhance the reliability of their
interpretations of urinary tract images.15,16 Our trial has certain limitations: our results may
not be applicable to children with different demographic or clinical characteristics or
children in locales where the choice of trimethoprim–sulfamethoxazole may be limited by
susceptibility patterns or clinical acceptability, and some of our subgroup analyses had
limited statistical power.
There are both similarities and differences between our findings and those of two other
trials.10,20 Craig et al. enrolled 576 Australian children under the age of 18 years with
stringently defined urinary tract infection in a placebo-controlled trial of trimethoprim–
sulfamethoxazole prophylaxis.10 Sixty-four percent of the children were girls. Twelve
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months of prophylaxis was associated with a reduction in the absolute risk of symptomatic
recurrences of 6 percentage points (number needed to treat, 14). However, pyuria was not
found at the index infection in 32% of the children, only 42% of the children had reflux,
41% had normal voiding studies, 17% did not undergo voiding cystourethrography, and
renal scanning with technetium-99m–labeled dimercaptosuccinic acid was performed after 1
year in only 27% of the children. In our trial, all children were younger than 6 years of age,
92% were girls, all were considered to have grade I to IV reflux, the diagnosis of infection
required the presence of pyuria, renal scanning was performed after 2 years in 76% of the
children, and the effect of prophylaxis was sustained over a 2-year period (number needed to
treat, 8).
Brandström et al. randomly assigned 203 Swedish children 12 to 23 months of age with
grade III or IV reflux to receive antimicrobial prophylaxis (with trimethoprim,
nitrofurantoin, or cefadroxil), endoscopic treatment, or surveillance only.20 A total of 37%
of the participants were boys, most of whom were uncircumcised. Clinicians and parents
were aware of the studygroup assignments, and bag-collected urine specimens were
permitted. Significant differences in outcome were noted only in girls. Girls in the
surveillance-only group had the highest incidence of febrile recurrence and the shortest time
to a first recurrence; girls who received antimicrobial prophylaxis had the lowest incidence
of renal scarring at 2 years of follow-up.21
Do our results support recent recommendations regarding urinary tract imaging in children
with a first febrile urinary tract infection?22 Many factors may influence that decision in
individual children, including the presence or absence of a family history of vesicoureteral
reflux, age, sex, and race, which affect the probability that vesicoureteral reflux is present;
the severity of the clinical course of the infection; the status of bladder and bowel function;
the cost of voiding cystourethrography and associated discomfort; the importance that
parents place on preventing recurrences (which sometimes result in alarming symptoms,
hospitalization, and parental work loss and which may influence the decision to proceed to
surgery in children found to have reflux); perceived parental ability to adhere to a
prophylaxis regimen; parental concern about potential long-term effects of prophylaxis, such
as the development of antimicrobial resistance and alterations of the microbiome; and most
important, the effectiveness of prophylaxis in preventing recurrences.
As long as evidence supporting the benefit of prophylaxis was dubious, the recommendation
of a watchful-waiting approach, without performance of a voiding cystourethrographic
study,22 seemed reasonable, because the imaging findings would not affect the nature of
treatment. However, our finding that antimicrobial prophylaxis was associated with a
reduced risk of recurrence may warrant reconsideration of that recommendation. Decision
analysis and cost-effectiveness analysis may help to clarify the clinical and financial trade-
offs, which may help clinicians and families reach more informed decisions about the
advisability of imaging in young children such as those in our study.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Enrollment, Randomization, and Follow-up of Children in the Trial
Capture of screening data commenced in November 2007; children were enrolled at various
clinical sites (emergency departments, radiology departments, and primary care, urology,
and nephrology offices), resulting in diverse criteria for screening (abnormal urinalysis
results, positive urine culture, and abnormal result of voiding cystourethrography [VCUG]).
Enrollment of children commenced in June 2007; 115 eligible children were enrolled
throughout the study without corresponding screening data for those not enrolled. Children
who were withdrawn from the study by a parent include some children who discontinued the
intervention because they met criteria for treatment failure or had a parent who preferred
prophylaxis to be prescribed. TMP-SMX denotes trimethoprim–sulfamethoxazole, UTI
urinary tract infection, and VUR vesicoureteral reflux.
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Figure 2. Time to First Recurrent Febrile or Symptomatic UTI
Shown are Kaplan–Meier estimates of the cumulative percentage of children who had a
recurrent febrile or symptomatic UTI according to study group. Fewer children assigned to
TMP-SMX prophylaxis had a UTI than children assigned to placebo (P<0.001 by log-rank
test). I bars indicate 95% confidence intervals.
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Figure 3. Effect of Antimicrobial Prophylaxis on the Risk of Febrile or Symptomatic UTI
Depicted are hazard ratios (rectangles) and 95% confidence intervals (horizontal lines) for a
first recurrent febrile or symptomatic UTI overall and for subgroups. P values are based on
Wald tests for the interaction of subgroup with study-group assignment. Hazard ratios of
less than 1.00 indicate that the risk of a recurrent febrile or symptomatic UTI was lower
among the children randomly assigned to antimicrobial prophylaxis than among those
assigned to placebo. BBD denotes bladder and bowel dysfunction.
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Baseline Demographic and Clinical Characteristics According to Study Group.*
Characteristic
Trimethoprim–Sulfamethoxazole (N
= 302) Placebo (N = 305) Overall (N = 607)
Age
 Median — mo 12 12 12
 Interquartile range — mo 5–31 6–30 6–31
 Group — no. (%)
  2–11 mo 151 (50.0) 147 (48.2) 298 (49.1)
  12–23 mo 48 (15.9) 59 (19.3) 107 (17.6)
  24–35 mo 43 (14.2) 36 (11.8) 79 (13.0)
  36–72 mo 60 (19.9) 63 (20.7) 123 (20.3)
Sex — no. (%)
 Male
  Circumcised 11 (3.6) 7 (2.3) 18 (3.0)
  Uncircumcised 14 (4.6) 17 (5.6) 31 (5.1)
 Female 277 (91.7) 281 (92.1) 558 (91.9)
Race — no./total no. (%)†
 White 245/298 (82.2) 237/299 (79.3) 482/597 (80.7)
 Black 10/298 (3.4) 17/299 (5.7) 27/597 (4.5)
 Multiracial 20/298 (6.7) 20/299 (6.7) 40/597 (6.7)
 Other 23/298 (7.7) 25/299 (8.4) 48/597 (8.0)
Hispanic ethnic group — no./total no. (%)† 31/300 (10.3) 46/304 (15.1) 77/604 (12.7)
Educational level of primary caregiver — no./total no. (%)
 High-school graduate or lower 78/299 (26.1) 80/303 (26.4) 158/602 (26.2)
 Some college or 2-yr degree 78/299 (26.1) 78/303 (25.7) 156/602 (25.9)
 College graduate or higher 143/299 (47.8) 145/303 (47.9) 288/602 (47.8)
Health insurance — no./total no. (%)
 Commercial 228/299 (76.3) 211/302 (69.9) 439/601 (73.0)
 Public‡ 71/299 (23.7) 91/302 (30.1) 162/601 (27.0)
Index UTI — no. (%)
 First episode 275 (91.1) 279 (91.5) 554 (91.3)
 Second episode 27 (8.9) 26 (8.5) 53 (8.7)
 Febrile only 96 (31.8) 100 (32.8) 196 (32.3)
 Symptomatic only 49 (16.2) 37 (12.1) 86 (14.2)
 Febrile and symptomatic 157 (52.0) 168 (55.1) 325 (53.5)
Susceptibility of index UTI to trimethoprim–
sulfamethoxazole— no./total no. (%)
 Resistant§ 55/278 (19.8) 65/293 (22.2) 120/571 (21.0)
 Sensitive 223/278 (80.2) 228/293 (77.8) 451/571 (79.0)

























= 302) Placebo (N = 305) Overall (N = 607)
Bladder and bowel dysfunction — no./total no. (%)¶ 34/63 (54.0) 37/63 (58.7) 71/126 (56.3)
Constipation — no./total no. (%)|| 8/65 (12.3) 8/64 (12.5) 16/129 (12.4)
Ultrasound abnormalities — no./total no. (%)
 Hydronephrosis** 19/300 (6.3) 13/302 (4.3) 32/602 (5.3)
 Ureter duplication 18/300 (6.0) 15/302 (5.0) 33/602 (5.5)
Highest degree of vesicoureteral reflux — no./total no. (%)††
 Grade I 35/301 (11.6) 33/301 (11.0) 68/602 (11.3)
 Grade II 123/301 (40.9) 131/301 (43.5) 254/602 (42.2)
 Grade III 118/301 (39.2) 112/301 (37.2) 230/602 (38.2)
 Grade IV 25/301 (8.3) 25/301 (8.3) 50/602 (8.3)
Bilateral vesicoureteral reflux — no./total no. (%) 146/300 (48.7) 141/300 (47.0) 287/600 (47.8)
Renal scarring — no./total no. (%)‡‡
 None 280/292 (95.9) 281/290 (96.9) 561/582 (96.4)
 Mild 1/292 (0.3) 0/290 1/582 (0.2)
 Moderate 3/292 (1.0) 2/290 (0.7) 5/582 (0.9)
 Severe 4/292 (1.4) 2/290 (0.7) 6/582 (1.0)
 Global atrophy 4/292 (1.4) 5/290 (1.7) 9/582 (1.5)
*
There were no significant differences between the study groups in any of the baseline characteristics (P>0.05). UTI denotes urinary tract infection.
†
Race and ethnic group were reported by the parent or guardian.
‡
Four children with no insurance were classified as having public insurance.
§
Included in this category are children whose index infection was caused by enterococcus or pseudomonas, was not tested for susceptibility to
trimethoprim–sulfamethoxazole, and was assumed to be resistant and children whose index infection was caused by bacteria that were resistant to
trimethoprim but were not tested for susceptibility to sulfamethoxazole.
¶
Bladder and bowel dysfunction was defined as a score of more than 6 for toilet-trained girls and more than 9 for toilet-trained boys on a modified
Dysfunctional Voiding Scoring System.17 Scores range from 0 to 30, with higher scores indicating greater bladder and bowel dysfunction.
||
Constipation was defined as two or more conditions according to modified criteria of the Paris Consensus on Childhood Constipation
Terminology Group18 (<3 bowel movements per week, >1 episode of fecal incontinence per week, passage of a large stool that obstructed the
toilet, retentive posture and behavior, and pain during defecation).
**
All 32 children had hydronephrosis of less than grade 4 on the Society for Fetal Urology scale.
††
Seven children with central assessment of no vesicoureteral reflux were included in grade I, and one child with central assessment of grade V
was included in grade IV (with enrollment based on local readings). Data on voiding cystourethrography for five children were missing because
images were not available for central evaluation.
‡‡
A total of 25 children did not undergo renal scanning with technetium-99m–labeled dimercaptosuccinic acid at baseline. Among 98 children (40
in the trimethoprim–sulfamethoxazole group and 58 in the placebo group) in whom scanning was performed less than 31 days after the index UTI,
scarring was identified in 1 child in the trimethoprim–sulfamethoxazole group. All other instances of scarring were identified in the 484 children
(252 in the trimethoprim–sulfamethoxazole group and 232 in the placebo group) in whom scanning was performed between 31 and 112 days after
the index UTI.
























Clinical Outcomes According to Study Group.
Outcome Trimethoprim–Sulfamethoxazole Placebo
Absolute Difference in Risk (95%
CI)
no. of children/total no. (%) percentage points
Recurrent febrile or symptomatic UTI*
 Children with missing 2-yr data classified
as having had an event (intention-to- treat
analysis)
77/302 (25.5) 114/305 (37.4)† 11.9 (4.6 to 19.2)
 Children with missing 2-yr data classified
as not having had an event (intention-to-treat
analysis)‡
39/302 (12.8) 72/305 (25.4)§ 12.6 (6.1 to 19.0)
 Children with missing 2-yr data omitted 39/264 (14.8) 72/263 (27.4)§ 12.6 (5.7 to 19.5)
Treatment failure‡¶ 14/302 (5.0) 27/305 (9.6)|| 4.5 (0.2 to 8.8)
Renal scarring**
 Overall 27/227 (11.9) 24/235 (10.2) −1.7 (−7.4 to 4.0)
 Severe†† 9/227 (4.0) 6/235 (2.6) −1.4 (−4.7 to 1.8)
 New‡‡ 18/220 (8.2) 19/227 (8.4) 0.2 (−4.9 to 5.3)
Any cortical defect 29/227 (12.8) 25/235 (10.6) −2.1 (−8.0 to 3.7)
Antimicrobial resistance
 Resistant Escherichia coli in stool 56/203 (27.6) 41/210 (19.5) −8.1 (−16.2 to 0.1)
 First recurrent febrile or symptomatic UTI
with resistant E. coli
19/30 (63.3)§§ 11/57 (19.3) −44.0 (−64.1 to −24.0)
 First recurrent febrile or symptomatic UTI
with any resistant pathogen
26/38 (68.4)§§ 17/69 (24.6) −43.8 (−61.7 to −25.8)
*
Included are 7 children (3 in the trimethoprim–sulfamethoxazole group and 4 in the placebo group) with febrile or symptomatic UTIs that
occurred before a missed 2-year visit. Imputation was applied to 38 children in the trimethoprim–sulfamethoxazole group and 42 children in the
placebo group.
†
P = 0.002 by log-rank test stratified according to five core sites.
‡
Percentages are based on Kaplan–Meier 2-year estimates.
§
P<0.001 by the log-rank test stratified according to five core sites.
¶
Treatment failure was defined as the occurrence of two febrile UTIs (28 children), one febrile UTI and three symptomatic UTIs (2 children), four
symptomatic UTIs (2 children), or new or worsening renal scarring (9 children).
||
P = 0.04 by the log-rank test stratified according to five core sites.
**
Renal scarring was defined as a decreased uptake of tracer that was associated with loss of contours or the presence of cortical thinning.
























Severe renal scarring was defined as scarring in more than 4 of 12 segments in at least one kidney or global atrophy characterized by a diffusely
scarred and shrunken kidney.
‡‡
New renal scarring was defined as scarring on the outcome renal scan with technetium-99m–labeled dimercaptosuccinic acid that was not
present at baseline.
§§
P<0.001 by the Cochran–Mantel–Haenszel test stratified according to five core sites.
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